Check-Cap (NSDQ:CHEK) said today it won conditional approval from the FDA for its investigational device exemption application to launch a pilot study of its C-Scan system. The Israel-based company’s C-Scan system is designed as an alternative to standard colon cancer screening methods.
Check-Cap wins conditional IDE approval for C-Scan pilot study
By Michael Tattory|
2019-01-17T16:29:33-04:00
December 13th, 2018|News|Comments Off on Check-Cap wins conditional IDE approval for C-Scan pilot study